Appendix DArticles Excluded at Full-Text Level

Publication Details

Reason for Exclusion: Study participants did not meet study population inclusion criteria and invalid study design

1.
Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: A summary of the literature. Journal of Urology. 2004;171(6 I):2122–2127. [PubMed: 15126770]
2.
Agrawal S, Dunsmuir WD. Molecular markers in prostate cancer. Part I: predicting lethality. Asian J Androl. 2009;11(1):14–21. [PMC free article: PMC3735212] [PubMed: 19050690]
3.
Andriole GL Jr. Screening for prostate cancer. BMJ. 2010;341:c4538. [PubMed: 20843936]
4.
Aziz DC, Barathur RB. Prostate-specific antigen and prostate volume: a meta-analysis of prostate cancer screening criteria. J Clin Lab Anal. 1993;7(5):283–92. [PubMed: 7692026]
5.
Belej K, Kaplan O, Kohler O, Kocarek J, Fojtik P. Prostate cancer gene 3 (PCA3) in prognosis after robotic assisted radical prostatectomy - Initial experience. European Urology, Supplements. 2010;9(6):630.
6.
Bjartell A. PSA and Prostate Cancer Screening: The Challenge of the New Millennium. European Urology. 2007;52(5):1284–1286. [PubMed: 17720305]
7.
Bostwick DG, Gould VE, Qian J, Susani M, Marberger M. Prostate cancer detected by uPM3: radical prostatectomy findings. Mod Pathol. 2006;19(5):630–3. [PubMed: 16528369]
8.
Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185(5):1650–5. [PMC free article: PMC3140702] [PubMed: 21419439]
9.
Chung JS, Choi HY, Song HR, Byun SS, Seo S, Song C, Cho JS, Lee SE, Ahn H, Lee ES, Kim WJ, Chung MK, Jung TY, Yu HS, Choi YD. Preoperative nomograms for predicting extracapsular extension in Korean men with localized prostate cancer: a multi-institutional clinicopathologic study. J Korean Med Sci. 2010;25(10):1443–8. [PMC free article: PMC2946653] [PubMed: 20890424]
10.
Connolly D, Hutton R, Keane PF. Re: Monique J. Roobol, Fritz H. Schroder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81. Eur Urol. 2011;59(3):e9. author reply e10-1. [PubMed: 21145647]
11.
Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol. 2006;175:1286–90. discussion 1290. [PubMed: 16515981]
12.
Crawford ED, Abrahamsson PA. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol. 2008;54(2):262–73. [PubMed: 18556114]
13.
D'Amico AV, Chen MH. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer. J Clin Oncol. 2009;27(22):3575–6. [PubMed: 19506151]
14.
Ding M, Cao X, Xu H, et al. Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene. PloS One. 2012;7(4):e35153. Epub 2012 Apr 11. [PMC free article: PMC3324420] [PubMed: 22509396]
15.
Dorff T, Tucker S. Prostate cancer in younger men poses clinical and research challenges. Community Oncology. 2009;6(9):427–430.
16.
Durand X, Moutereau S, Xylinas E, de la Taille A. Progensa PCA3 test for prostate cancer. Expert Rev Mol Diagn. 2011;11(2):137–44. [PubMed: 21405964]
17.
Durand X, Xylinas E, Radulescu C, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int. 2012 Jul;110(1):43–9. [PubMed: 22221521]
18.
Ekwueme DU, Stroud LA, Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prev Chronic Dis. 2007;4(4):A100. [PMC free article: PMC2099265] [PubMed: 17875244]
19.
Ficarra V, Novara G, Zattoni F. The role of the prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening. Eur Urol. 2010;58(4):482–4. discussion 484-5. [PubMed: 20685032]
20.
Fichtner J. The management of prostate cancer in patients with a rising prostate-specific antigen level. BJU International. 2000;86(2):181–190. [PubMed: 10886105]
21.
Fontenete S, Silva J, Teixeira AL, et al. Controversies in using urine samples for Prostate Cancer detection: PSA and PCA3 expression analysis. International Braz J Urol. 2011 Nov-Dec;37(6):719–26. [PubMed: 22234006]
22.
Fontenete S, Nogueira A, Pina F, et al. Molecular study of the PCA3 gene: genotypic analysis of PCA3 polymorphism -845G>A and metastatic prostate cancer. Genetic testing and molecular biomarkers. 2012 May;16(5):418–22. [PubMed: 22288776]
23.
Galasso F, Giannella R, Bruni P, Giulivo R, Barbini VR, Disanto V, Leonardi R, Pansadoro V, Sepe G. PCA3: a new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study. Arch Ital Urol Androl. 2010;82(1):5–9. [PubMed: 20593708]
24.
Goyal SR, Talib VH, Khurana SK. An overview of PSA/percent free PSA with special reference to recent trends in diagnosis of prostatic cancer. Indian J Pathol Microbiol. 1999;42(2):171–8. [PubMed: 10639780]
25.
Gregorio EP, Grando JP, Saqueti EE, Almeida SH, Moreira HA, Rodrigues MA. Comparison between PSA density, percent free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/mL. Int Braz J Urol. 2007;33(2):151–60. [PubMed: 17488533]
26.
Grillo-Lopez AJ. The ODAC chronicles: Part 5. Prostate cancer endpoints. Expert Review of Anticancer Therapy. 2005;5(3):405–410. [PubMed: 16001947]
27.
Grubb RL 3rd, Andriole GL. Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy? Nat Clin Pract Urol. 2006;3(6):306–7. [PubMed: 16763640]
28.
Gulkesen KH, Koksal IT, Bilge U, Saka O. Comparison of methods for prediction of prostate cancer in Turkish men with PSA levels of 0-10 ng/mL. J BUON. 2010;15(3):537–42. [PubMed: 20941824]
29.
Haid M, Rabin D, King KM, Feinstein CM, Janson KL, Levine SR, Mutchnik DL, Lambiase EA, Bradley R. Digital rectal examination, serum prostate specific antigen, and prostatic ultrasound: how effective is this diagnostic triad? J Surg Oncol. 1994;56(1):32–8. [PubMed: 7513772]
30.
Haythorn MR, Ablin RJ. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomarkers in medicine. 2011;5(4):515–26. [PubMed: 21861672]
31.
Henderson AJ, Ghani KR, Cook J, Fahey M, Schalken J, Thilagarajah R. The role of PCA3 testing in patients with a raised prostate-specific antigen level after Greenlight photoselective vaporization of the prostate. J Endourol. 2010;24(11):1821–4. [PubMed: 20964483]
32.
Herrmann TR, Merseburger AS, Burchardt M. Prostate cancer: novel aspects of diagnostics and surgical technology. World J Urol. 2010;28(6):665. [PubMed: 20976601]
33.
Horwich A. Prostate cancer management. Annals of Oncology. 2004;15(SUPPL. 4):iv307–iv312. [PubMed: 15477327]
34.
Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev. 2006;3:CD004720. [PubMed: 16856057]
35.
Ingram DG, Kattan MW. Risk grouping versus risk continuum in patients with clinically localized prostate cancer: a taxometric test. J Urol. 2010;184(5):1937–41. [PubMed: 20846685]
36.
Jansen FH, Roobol M, Jenster G, Schroder FH, Bangma CH. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol. 2009;55(3):563–74. [PubMed: 19058905]
37.
Kakehi Y. Re: Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol. 2011;60(1):178–9. [PubMed: 21640694]
38.
Karakiewicz PI, Hutterer GC. Predicting outcomes in patients with urologic cancers. Curr Opin Support Palliat Care. 2007;1(3):153–68. [PubMed: 18685357]
39.
Kattan MW, Scardino PT. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer. 2002;1(2):90–6. [PubMed: 15046699]
40.
Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The ‘CaP Calculator’: an online decision support tool for clinically localized prostate cancer. BJU Int. 2010;105(10):1417–22. [PMC free article: PMC3090683] [PubMed: 20346051]
41.
Kirby R. PCA3 improves diagnosis of prostate cancer. Practitioner. 2007;251(1690):18, 21, 23. [PubMed: 17290852]
42.
Kirby R, Fitzpatrick JM. Optimising repeat prostate biopsy decisions and procedures. BJU Int. 2012 Jun;109(12):1750–4. [PubMed: 22192873]
43.
Langley S, Ahmed HU, Al-Qaisieh B, et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int. 2012;109(SUPPL. 1):7–16. [PubMed: 22239224]
44.
Lavin MF, Clarke R, Gardiner RA. Differential expression of PCA3 and BMCC1 in prostate cancer. Prostate. 2009;69(16):1713–4. author reply 1715. [PubMed: 19852006]
45.
Laskiewicz L, Jiang Z, Altieri DC, et al. The search for a better prostate cancer biomarker. Journal of Urology. 2011;186(5):1758–59. [PubMed: 21944983]
46.
Law M. Screening without evidence of efficacy. British Medical Journal. 2004;328(7435):301–302. [PMC free article: PMC338086] [PubMed: 14764465]
47.
Lee GL, Dobi A, Srivastava S. Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol. 2011;8(3):123–4. [PubMed: 21394175]
48.
Loeb S. Does PCA3 help identify clinically significant prostate cancer? Eur Urol. 2008;54(5):980–1. [PubMed: 18684556]
49.
Loeb S, Partin AW. PCA3 Urinary Biomarker for Prostate Cancer. Rev Urol. 2010;12(4):e205–6. [PMC free article: PMC3020285] [PubMed: 21234266]
50.
Loeb S. Prostate cancer: is PSA velocity useful? Nat Rev Urol. 2009;6(6):305–6. [PubMed: 19498408]
51.
Lorusso V. Prostate carcinoma. Tumori. 2002;88(SUPPL. 1):S125–S127. [PubMed: 11989904]
52.
Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med. 2009;60:139–51. [PubMed: 18947298]
53.
Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol. 2006;176(2):439–49. [PMC free article: PMC2875171] [PubMed: 16813862]
54.
Martin AJ, Cheli CD, Sterling K, Ward M, Pollard S, Lifsey D, Mercante D, Martin L, Rayford W. Prostate specific antigen isoforms and human glandular kallikrein 2 - Which offers the best screening performance in a predominantly black population? Journal of Urology. 2006;175(1):104–107. [PubMed: 16406882]
55.
Martinez CH, Chalasani V, Chin J. Molecular biomarkers in prostate cancer. Expert Opinion on Medical Diagnostics. 2009;3(4):345–353. [PubMed: 23485204]
56.
Nelson JB, Allen AR, Hulting SM, Isaacson JD, Sleep DS. Prostate-specific antigen doubling time as a predictor of prostate cancer disease progression und survival. 2004;22:394. Abstract [Journal unknown]
57.
Ng L, Karunasinghe N, Benjamin CS, et al. Beyond PSA: Are new prostate cancer biomarkers of potential value to New Zealand doctors? New Zealand Medical Journal. 2012;125(1353):59–86. [PubMed: 22522272]
58.
Nickel JC, Speakman M. Should we really consider Gleason 6 prostate cancer? BJU Int. 2012;109(5):645–46. [PubMed: 22193242]
59.
Nogueira L, Corradi R, Eastham JA. Other biomarkers for detecting prostate cancer. BJU Int. 2010;105(2):166–9. [PubMed: 19930175]
60.
Oakley N. Clinical implications of prostate-specific antigen (PSA) Current Opinion in Urology. 1998;8(5):401–406. [PubMed: 17039019]
61.
Oliveira M, Marques V, Carvalho AP, Santos A. Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction. BJU International. 2011;107(11):1780–1783. [PubMed: 20883487]
62.
Pepe P, Aragona F. Does an inflammatory pattern at primary biopsy suggest a lower risk for prostate cancer at repeated saturation prostate biopsy? Urol Int. 2011;87(2):171–74. [PubMed: 21778685]
63.
Pelekanos A, Beardi J, Jonas D, Oremek GM. Isoforms of PSA (prostate-specific antigen) in the diagnosis of prostate cancer. Clinical and Experimental Medical Letters. 2008;49(1):23–25.
64.
Puppo P. Repeated Negative Prostate Biopsies with Persistently Elevated or Rising PSA: A Modern Urologic Dilemma. European Urology. 2007;52(3):639–641. [PubMed: 17451871]
65.
Reddy GK, Gibson TB. Identification of potential therapeutic targets using microarray data in prostate cancer: A large-scale metaanalysis by oncomine. Clinical Prostate Cancer. 2005;3(4):209–210.
66.
Riesterer O, Milas L, Ang KK. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol. 2007;25(26):4075–83. [PubMed: 17827456]
67.
Reni M, Bolognesi A. Prognostic value of prostate specific antigen before, during and after radiotherapy. Cancer Treat Rev. 1998;24:91–99. Review. [PubMed: 9728419]
68.
Roberson CD, Atay S, Gercel-Taylor C, et al. Tumor-derived exosomes as mediators of disease and potential diagnostic biomarkers. Cancer Biomarkers. 2010;8(4-5):281–87. [PubMed: 22045359]
69.
Roobol MJ, Schroder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, van Leeuwen PJ. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (>/= 100) Eur Urol. 2010;58(6):893–9. [PubMed: 20933321]
70.
Roobol MJ, Carlsson S, Hugosson J. Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductions. Evid Based Med. 2011;16(1):20–1. [PubMed: 21228057]
71.
Roobol MJ. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol. 2011;21(3):225–9. [PubMed: 21301341]
72.
Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 2001;165(5):1562–8. [PubMed: 11342918]
73.
Salagierski M, Schalken JA. PCA3 and TMPRSS2-ERG: Promising biomarkers in prostate cancer diagnosis. Cancers. 2010;2(3):1432–1440. [PMC free article: PMC3837315] [PubMed: 24281166]
74.
Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem. 2008;54(12):1951–60. [PubMed: 18927246]
75.
Satake N, Ohori M, Yu C, Kattan MW, Ohno Y, Miyakawa A, Hatano T, Tachibana M. Development and internal validation of a nomogram predicting extracapsular extension in radical prostatectomy specimens. Int J Urol. 2010;17(3):267–72. [PubMed: 20132361]
76.
Schalken JA. Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time. European Urology, Supplements. 2009;8(3):97–102.
77.
Schellhammer P. Clinical trials in prostate cancer. BJU International. 2003;92(3):186–187. [PubMed: 12887463]
78.
Schilling D, de Reijke T, Tombal B, de la Taille A, Hennenlotter J, Stenzl A. The Prostate Cancer gene 3 assay: indications for use in clinical practice. BJU Int. 2009;105(4):452–5. [PubMed: 19930176]
79.
Schroder FH, Denis LJ, Roobol M. The story of the European Randomized Study of Screening for Prostate Cancer. BJU International, Supplement. 2003;92(2):1–13. [PubMed: 14983946]
80.
Sioss JA, Bhiladvala R, Pan W, et al. Nanoresonator chip-based RNA sensor strategy for detection of circulating tumor cells: response using PCA3 as a prostate cancer marker. Nanomedicine: Nanotechnology, Biology, and Medicine. Epub 2011 Nov 22. [PMC free article: PMC3290699] [PubMed: 22115599]
81.
Smith DP, Banks E, Clements MS, Gardiner RA, Armstrong BK. Evidence-based uncertainty: recent trial results on prostate-specific antigen testing and prostate cancer mortality. Med J Aust. 2009;191(4):199–200. [PubMed: 19705979]
82.
Stephan C, Rittenhouse H, Cammann H, Lein M, Schrader M, Deger S, Miller K, Jung K. New markers and multivariate models for prostate cancer detection. Anticancer Res. 2009;29(7):2589–600. [PubMed: 19596933]
83.
Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N, Staffurth J. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess. 2009;13(5):iii, xi–xiii, 1–219. [PubMed: 19128541]
84.
Thanigasalam R, Mancuso P, Tsao K, Rashid P. Prostate-specific antigen velocity (PSAV): a practical role for PSA? ANZ J Surg. 2009;79(10):703–6. [PubMed: 19878164]
85.
Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. ScientificWorldJournal. 2010;10:1919–31. [PubMed: 20890581]
86.
Tzimagiorgis GE, Michailidou Z, Kritis A, et al. Recovering circulating extracellular or cell-free RNA from bodily fluids. Cancer Epidemiology. 2011;35(6):580–89. [PubMed: 21514265]
87.
Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, Bjork T, Berglund G, Vickers AJ, Lilja H. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol. 2008;26(6):835–41. [PubMed: 18281654]
88.
van den Bergh RC, Roemeling S, Roobol MJ, Wolters T, Schroder FH, Bangma CH. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. Eur Urol. 2008;54(3):505–16. [PubMed: 18585845]
89.
Vickers J, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009;27(3):398–403. [PMC free article: PMC2645854] [PubMed: 19064972]
90.
Vlaeminck-Guillem V, Bandel M, Cottancin M, et al. Chronic prostatitis does not influence urinary PCA3 score. Prostate. 2012 Apr;72(5):549–54. [PubMed: 21761426]
91.
Whittemore DE, Hick EJ, Carter MR, Moul JW, Miranda-Sousa AJ, Sexton WJ. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol. 2008;179(2):516–22. discussion 522. [PubMed: 18076949]
92.
Zietman AL. Time to second prostate specific antigen (PSA) failure is a surrogate endpoint for prostate cancer death in prospective trials of therapy for localized disease. 1995;32:229. Abstract no: 1013, [Journal unknown] [PubMed: 8607241]

Reason for Exclusion: Study participants did not meet study population inclusion criteria

1.
Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster RS, Andriole GL, Groskopf J. Prostate Cancer Gene 3 Score Predicts Prostate Biopsy Outcome in Men Receiving Dutasteride for Prevention of Prostate Cancer: Results From the REDUCE Trial. Urology. 2011;78(2):380–5. [PubMed: 21820580]
2.
Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer research. 2008;68:645–9. [PMC free article: PMC2998181] [PubMed: 18245462]
3.
Saad F. UPM3: review of a new molecular diagnostic urine test for prostate cancer. The Canadian jounal of urology. 2005;12 Suppl 1:40–43. discussion 99-100. [PubMed: 15780164]
4.
Salami SS, Schmidt F, Laxman B, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urologic oncology. 2011 May 19 Web posting prior to publication. [PMC free article: PMC3210917] [PubMed: 21600800]
5.
Talesa VN, Antognelli C, Del Buono C, Stracci F, Serva MR, Cottini E, Mearini E. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers. Cancer Biomark. 2009;5(6):241–51. [PubMed: 20037200]

Reason for Exclusion: Invalid Study Design

1.
Benchikh A, Savage C, Cronin A, Salama G, Villers A, Lilja H, Vickers A. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening. France BMC Cancer. 2010;10:635. [PMC free article: PMC2996396] [PubMed: 21092177]
2.
Benecchi L, Pieri AM, Destro Pastizzaro C, Potenzoni M. Optimal measure of PSA kinetics to identify prostate cancer. Urology. 2008;71(3):390–4. [PubMed: 18342170]
3.
Berger AP, Deibl M, Strasak A, Bektic J, Pelzer AE, Klocker H, Steiner H, Fritsche G, Bartsch G, Horninger W. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology. 2007;69(1):134–8. [PubMed: 17270635]
4.
Capitanio U, Briganti A, Gallina A, Suardi N, Karakiewicz PI, Montorsi F, Scattoni V. Predictive models before and after radical prostatectomy. Prostate. 2010;70(12):1371–8. [PubMed: 20623635]
5.
Chun FK, Graefen M, Briganti A, Gallina A, Hopp J, Kattan MW, Huland H, Karakiewicz PI. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol. 2007;51(5):1236–40. discussion 1241-3. [PubMed: 16945477]
6.
Chung JS, Choi HY, Song HR, Byun SS, Seo SI, Song C, Cho JS, Lee SE, Ahn H, Lee ES, Hwang TK, Kim WJ, Chung MK, Jung TY, Yu HS, Choi YD. Nomogram to predict insignificant prostate cancer at radical prostatectomy in Korean men: a multi-center study. Yonsei Med J. 2011;52(1):74–80. [PMC free article: PMC3017711] [PubMed: 21155038]
7.
D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol. 2006;176(6 Pt 2):S11–5. [PubMed: 17084157]
8.
Eskicorapci SY, Turkeri L, Karabulut E, Cal C, Akpinar H, Baltaci S, Baykal K, Kattan MW, Ozen H. Validation of two preoperative Kattan nomograms predicting recurrence after radical prostatectomy for localized prostate cancer in Turkey: a multicenter study of the Uro-oncology Society. Urology. 2009;74(6):1289–95. [PubMed: 19589584]
9.
Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology. 2003;61(3):589–95. [PubMed: 12639653]
10.
Haroun AA, Hadidy AS, Awwad ZM, Nimri CF, Mahafza WS, Tarawneh ES. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer. Saudi J Kidney Dis Transpl. 2011;22(2):291–7. [PubMed: 21422628]
11.
Haroun AA. New indicator for prostate gland biopsy when malignancy is in question. Saudi J Kidney Dis Transpl. 2011;22(1):61–6. [PubMed: 21196614]
12.
Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44(1):8–15. discussion 15-6. [PubMed: 12814669]
13.
Hoffman RM, Clanon DL, Chavez M, Peirce JC. Using multiple cutpoints for the free-to-total prostate specific antigen ratio improves the accuracy of prostate cancer detection. Prostate. 2002;52(2):150–8. [PubMed: 12111706]
14.
Hoffman RM, Clanon DL, Littenberg B, Frank JJ, Peirce JC. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med. 2000;15(10):739–48. [PMC free article: PMC1495603] [PubMed: 11089718]
15.
Kefi A, Irer B, Ozdemir I, Tuna B, Goktay Y, Yorukoglu K, Esen A. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range. Urol Int. 2005;75(3):222–6. [PubMed: 16215309]
16.
Kirby RS, Fitzpatrick JM, Irani J. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3) BJU Int. 2009;103(4):441–5. [PubMed: 19154510]
17.
Klatte T, Waldert M, de Martino M, et al. Age-specific PCA3 score reference values for diagnosis of prostate cancer. World J Urol. 2012 Jun;30(3):405–10. [PubMed: 21877172]
18.
Kobayashi T, Kawahara T, Nishizawa K, Ogura K, Mitsumori K, Ide Y. Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection. Int J Urol. 2005;12(10):881–5. [PubMed: 16323981]
19.
Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology. 2006;67(4):762–8. [PubMed: 16600352]
20.
Loeb S, Roehl KA, Thaxton CS, Catalona WJ. Combined prostate-specific antigen density and biopsy features to predict “clinically insignificant” prostate cancer. Urology. 2008;72(1):143–7. [PubMed: 18436287]
21.
Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter HB. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol. 2008;54(5):1073–80. [PMC free article: PMC2582974] [PubMed: 18614274]
22.
Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, Shariat SF, Vickers AJ. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol. 2010;58(5):687–700. [PMC free article: PMC4119802] [PubMed: 20727668]
23.
Lughezzani G, Budaus L, Isbarn H, Sun M, Perrotte P, Haese A, Chun FK, Schlomm T, Steuber T, Heinzer H, Huland H, Montorsi F, Graefen M, Karakiewicz PI. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol. 2010;57(4):562–8. [PubMed: 20018437]
24.
Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent percent free PSA for early detection of prostate cancer: Impact of changing disease demographics. Urology. 2001;57(6):1105–1111. [PubMed: 11377319]
25.
Moreira AM, Presti JC Jr., Aronson WJ, Terris MK, Kane CJ, Amling CL, Sun LL, Moul JW, Freedland SJ. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. Int J Urol. 2010;17(11):914–22. [PMC free article: PMC3188446] [PubMed: 20880361]
26.
Mutlu N, Turkeri LN, Yencilek F, Demir A, Emerk K. Complexed prostate specific antigen: better test in the diagnosis of prostate cancer for the clinically relevant 2.5-4 ng/ml total PSA range. Can J Urol. 2009;16(2):4558–67. [PubMed: 19364428]
27.
Okihara K, Ukimura O, Nakamura T, Mizutani Y, Kawauchi A, Naya Y, Uchida M, Ogiwara T, Miki T. Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men? European Urology. 2004;46(1):57–64. [PubMed: 15183548]
28.
Okegawa T, Kinjo M, Ohta M, Miura I, Horie S, Nutahara K, Higashihara E. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL. Int J Urol. 2003;10(4):201–6. [PubMed: 12657099]
29.
Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM. Biomarkers for prostate cancer detection. J Urol. 2007;178(6):2252–9. [PubMed: 17936845]
30.
Park HK, Lee KY, Kim KH, Jung H, Yoon SJ, Kim TB. Intermediate versus low or high prostate-specific antigen density level: comparison of cancer detection rate between 12- and 18-core prostate biopsy. Scand J Urol Nephrol. 2010;44(6):391–8. [PubMed: 20695726]
31.
Parsons JK, Brawer MK, Cheli CD, Partin AW, Djavan R. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA. BJU Int. 2004;94(1):47–50. [PubMed: 15217429]
32.
Prensner JR, Rubin MA, Wei JT, et al. Beyond PSA: The next generation of prostate cancer biomarkers. Science Translational Medicine. 2012;4(127):127rv3. [PMC free article: PMC3799996] [PubMed: 22461644]
33.
Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P, Allen NE. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005;48(3):386–99. discussion 398-9. [PubMed: 15982797]
34.
Roobol MJ, van der Cruijsen IW, Schroder FH. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam) Urology. 2004;63(5):892–7. discussion 897-9. [PubMed: 15134973]
35.
Rubio-Briones J, Fernández-Serra A, Ramírez L, Rubio L, Collado A, Casanova J, Gómez-Ferrer A, Ricós Jv, Monrós JL, Dumont R, Ortiz B, Iborra I, García-Casado Z, Solsona E, López-Guerrero JA. Actas Urol Esp. 2011 Nov-Dec;35(10):589–96. Epub 2011 Jun 22. Spanish / English translation. [PubMed: 21700365]
36.
Ruiz-Aragon J, Marquez-Pelaez S. Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis. Actas Urol Esp. 2010;34:346–55. [translated into English by the journal] [PubMed: 20470697]
37.
San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol. 2011;185(2):471–6. [PubMed: 21167525]
38.
Schroder A, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol. 2008;54(2):274–90. [PubMed: 18511177]
39.
Sciarra A, Panebianco V, Cattarino S, et al. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy. BJU Int. Epub 2012 May 4. [PubMed: 22564540]
40.
Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology. 2009;73(2):363–8. [PubMed: 18995890]
41.
Shariat SF, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res. 2008;14(14):4400–7. [PubMed: 18628454]
42.
Shariat SF, Karakiewicz PI, Margulis V, Kattan MW. Inventory of prostate cancer predictive tools. Curr Opin Urol. 2008;18(3):279–96. [PubMed: 18382238]
43.
Song JM, Kim CB, Chung HC, Kane RL. Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: a meta-analysis for this diagnostic triad of prostate cancer in symptomatic korean men. Yonsei Med J. 2005;46(3):414–24. [PMC free article: PMC2815820] [PubMed: 15988815]
44.
Sozen S, Eskicorapci S, Kupeli B, Irkilata L, Altinel M, Ozer G, Uygur C, Alkibay T, Ozen H. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study. Eur Urol. 2005;47(3):302–7. [PubMed: 15716190]
45.
Stephan G, Stroebel M, Heinau A, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer. 2005;104(5):993–1003. [PubMed: 16007682]
46.
Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr., Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27(26):4300–5. [PMC free article: PMC3651598] [PubMed: 19636023]
47.
Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. Sci Transl Med. 2011;3(94):94ra72. [PMC free article: PMC3245713] [PubMed: 21813756]
48.
Verma M, Patel P. Biomarkers in prostate cancer epidemiology. Cancers. 2011;3(4):3773–98. [PMC free article: PMC3763396] [PubMed: 24213111]
49.
Vlaeminck-Guillem V, Ruffion A, Andre J, Devonec M, Paparel P. Urinary prostate cancer 3 test: toward the age of reason? Urology. 2010;75(2):447–53. [PubMed: 19586654]
50.
Wang Y, Sun G, Pan JG, Guo ZJ, Li T. Performance of tPSA and f/tPSA for prostate cancer in Chinese. A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2006;9(4):374–8. [PubMed: 16926855]
51.
Ward JF. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer? Nat Clin Pract Urol. 2006;3(6):310–1. [PubMed: 16763642]
52.
Yuasa T, Tsuchiya N, Kumazawa T, Inoue T, Narita S, Saito M, Horikawa Y, Satoh S, Habuchi T. Characterization of prostate cancer detected at repeat biopsy. BMC Urology. 2008;8(1) [PMC free article: PMC2606675] [PubMed: 19000320]